Skip to main navigation
Molecular Partners

> Top Menu

  • Partnering
  • Careers
  • Contact Us

> Investor Relations

  • About Us
  • DARPin Biology
  • The DARPin Platform
  • Pipeline
  • Investors
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Scientific Documents
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team & Board of Directors
      • Committee Composition
      • Major Shareholders
      • Management Transactions
    • ESG Overview
    • Ethics & Compliance
    • Financials & Filings
      • SEC Filings
      • Financial Reports
    • General Meeting
    • IR Resources
      • Email Alerts
      • Contact IR

> Top Menu

  • Partnering
  • Careers
  • Contact Us

> Investor Relations

  • About Us
  • DARPin Biology
  • The DARPin Platform
  • Pipeline
  • Investors
    • « Back
    • Overview
    • News & Events
      • « Back
      • News Releases
      • Events
      • Presentations
    • Scientific Documents
    • Stock Information
      • « Back
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • « Back
      • Documents & Charters
      • Management Team & Board of Directors
      • Committee Composition
      • Major Shareholders
      • Management Transactions
    • ESG Overview
    • Ethics & Compliance
    • Financials & Filings
      • « Back
      • SEC Filings
      • Financial Reports
    • General Meeting
    • IR Resources
      • « Back
      • Email Alerts
      • Contact IR

Investors

Investors

SHARE PRICE

> View All Stock

  • Detailed Share Information
Latest News
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

> View All News

  • All News
Upcoming Events
More events are coming soon.

> View All Events

  • All Events
Latest Presentation
November 3, 2023
Corporate Presentation - November 2023
August 24, 2023
H1 2023 Results Presentation
May 26, 2023
RBC Healthcare Conference Presentation

> View All Presentations

  • All Presentations
Latest Financial Documents
October 26, 2023
Q3 2023 Financial Statement
August 24, 2023
H1 2023 Business Update and Financial Statements
April 19, 2023
Molecular Partners statement regarding Passive Foreign Investment Company status

> View All Reports

  • All Annual Report
Seth Lewis

Seth Lewis,
SVP Investor Relations and Strategy

Contact Seth

STAY INFORMED

Subscribe to email alerts of your choosing

SUBSCRIBE

Institutional investors:

  REQUEST 1-1 / CALL

powered by schedulR

> Footer Menu

  • Cookie Notice
  • Privacy & Disclaimer
  • Contact Us

> Footer Social

© 2023 Molecular Partners.